NASDAQ$RIGL
Rigel Pharmaceuticals Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported strong first quarter with increased net product sales and advanced launch of REZLIDHIA.
Rigel Pharmaceuticals reported a net loss of $13.5 million for the first quarter of 2023, with total revenues of $26.1 million. The company saw a 47% increase in net product sales compared to Q1 2022, driven by TAVALISSE and REZLIDHIA sales.
- Net product sales increased by 47% compared to Q1 2022.
- TAVALISSE net product sales increased by 38% from the same period in 2022, reaching $22.3 million.
- REZLIDHIA net product sales were $1.5 million.
- Net loss decreased to $13.5 million, compared to a net loss of $27.4 million for the same period of 2022.
Headline financials
Revenue & EPS history
Rigel · Revenue · Quarterly
$26.1M
Revenue by segment
Rigel · $2M total across 1 segment · Q2 2023
- Collaboration Revenue$2M-82.3%100.0%
Forward guidance
Rigel has established a strong foundation for its hematology-oncology business to successfully deliver growth in both TAVALISSE and REZLIDHIA, and to advance its development programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+0.2%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+2.8%
Avg return
30 days after
38%
25 / 65 earnings
Positive
+46.4%
Q3 2024
Best reaction
-18.7%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.8% | -11.8% | +2.3% | |
| Q4 2025 | -10.2% | -15.0% | -16.6% | |
| Q3 2025 | -2.6% | +10.6% | +35.4% | |
| Q1 2025 | +0.9% | +1.9% | +17.7% | |
| Q4 2024 | -8.1% | -11.5% | -21.9% | |
| Q3 2024 | +46.4% | +80.5% | +68.8% | |
| Q2 2024 | +12.2% | +16.0% | +52.4% | |
| Q1 2024 | -18.7% | -19.7% | -21.3% | |
| Q4 2023 | +6.1% | +6.8% | -12.2% | |
| Q3 2023 | +5.8% | -2.4% | +35.7% | |
| Q2 2023 | -6.5% | -11.6% | -17.4% | |
| Q1 2023 | -3.4% | -0.8% | +17.6% | |
| Q4 2022 | +17.8% | +4.6% | -17.8% | |
| Q3 2022 | +5.3% | +4.3% | +18.6% | |
| Q2 2022 | +16.5% | +25.6% | +27.3% | |
| Q1 2022 | +7.3% | -9.8% | -32.5% | |
| Q4 2021 | +21.1% | +21.1% | +19.1% | |
| Q3 2021 | -1.7% | -8.8% | -26.3% | |
| Q2 2021 | -7.2% | -5.2% | +3.2% | |
| Q1 2021 | -5.2% | -7.8% | +15.7% | |
| Q4 2020 | -14.3% | -14.1% | -23.3% | |
| Q3 2020 | -3.0% | +1.5% | +14.1% | |
| Q2 2020 | +3.7% | +6.2% | -4.5% | |
| Q1 2020 | -2.2% | -2.7% | +2.2% | |
| Q4 2019 | -2.3% | +0.5% | -27.6% | |
| Q3 2019 | -1.9% | +4.7% | -5.1% | |
| Q2 2019 | +8.1% | +1.9% | -15.7% | |
| Q1 2019 | -5.5% | -6.7% | -14.7% | |
| Q4 2018 | -0.9% | -1.8% | +13.7% | |
| Q3 2018 | +7.2% | -2.7% | -3.8% | |
| Q2 2018 | +10.2% | +1.1% | +16.8% | |
| Q1 2018 | +5.3% | +7.2% | -10.0% | |
| Q4 2017 | +13.5% | +14.5% | -18.1% | |
| Q3 2017 | +1.1% | +1.6% | +2.4% | |
| Q2 2017 | -1.3% | +1.7% | +7.6% | |
| Q1 2017 | -9.9% | -9.2% | -19.1% | |
| Q4 2016 | +2.6% | +0.8% | +14.3% | |
| Q3 2016 | -3.1% | +1.5% | -3.5% | |
| Q2 2016 | +14.3% | +22.7% | +37.5% | |
| Q1 2016 | -10.9% | — | — | |
| Q4 2015 | -6.3% | — | — | |
| Q3 2015 | +8.9% | — | — | |
| Q2 2015 | +4.6% | — | — | |
| Q1 2015 | -10.5% | — | — | |
| Q4 2014 | -1.0% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | -10.6% | — | — | |
| Q4 2013 | +17.5% | — | — | |
| Q3 2013 | -9.3% | — | — | |
| Q2 2013 | +2.8% | — | — | |
| Q1 2013 | -0.6% | — | — | |
| Q4 2012 | +5.5% | — | — | |
| Q3 2012 | +2.7% | — | — | |
| Q2 2012 | -7.1% | — | — | |
| Q1 2012 | -2.1% | — | — | |
| Q4 2009 | -9.0% | — | — | |
| Q4 2011 | -9.0% | — | — | |
| Q3 2010 | -5.9% | — | — | |
| Q3 2011 | -5.9% | — | — | |
| Q2 2010 | -3.3% | — | — | |
| Q4 2010 | -3.3% | — | — | |
| Q2 2011 | -3.3% | — | — | |
| Q1 2011 | -11.5% | — | — | |
| Q1 2010 | -5.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro